has function has role immunizes against disease immunizes recipient prostate cancer Homo sapiens live attenuated vaccine therapeutic vaccine function vaccine in clinical trial role prostate cancer vaccine Brachyury-expressing Modified Vaccinia Ankara-TRICOM Vaccine A cancer vaccine composed of a replication-deficient, attenuated derivative of the vaccinia virus strain Ankara expressing both a CD8+ T-cell epitope from the brachyury protein and a triad of T-cell co-stimulatory molecules (MVA Brachyury-TRICOM), with potential immunomodulating and antineoplastic activities. Upon subcutaneous administration of the brachyury-expressing modified vaccinia Ankara (MVA)-TRICOM vaccine, the expressed brachyury protein induces specific CD8+ and CD4+ T-cell responses against brachyury-expressing tumor cells. This causes both tumor cell lysis and a decrease in the growth of brachyury-expressing tumor cells. Brachyury, a member of the T-box family of transcription factors that is overexpressed in numerous cancer cell types, is correlated with increased epithelial-mesenchymal transition (EMT), cancer resistance and cancer progression. TRICOM, a triad of three human T-cell co-stimulatory molecules, B7.1, ICAM-1 and LFA-3, enhances antigen-specific T-cell activation. VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5439 Eliyas Asfaw Ibrahim Seleznev 5439 https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/v?id=NCI-2022-05711&r=1 Oliver He Jie Zheng Gene name: CD8A 925 cancer vaccine https://github.com/vaccineontology/VO/issues/310 therapeutic cancer vaccine live attenuated vaccine role